ArticleJournal of comparative effectiveness research2023

Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.

Amrita Krishnan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.